[
    [
        {
            "time": "",
            "original_text": "中银基金旗下部分产品二季报出炉，个别债基标的受监管处罚，刘潇大幅加仓云南白药、丽珠集团、大参林",
            "features": {
                "keywords": [
                    "中银基金",
                    "二季报",
                    "债基",
                    "监管处罚",
                    "刘潇",
                    "云南白药",
                    "丽珠集团",
                    "大参林"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "中银基金旗下部分产品二季报出炉，个别债基标的受监管处罚，刘潇大幅加仓云南白药、丽珠集团、大参林",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]